Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer
Lin, Jessica Jiyeong, Johnson, Ted, Lennerz, Jochen K, Lee, Charlotte, Hubbeling, Harper Grace, Yeap, Beow Y., Dagogo-Jack, Ibiayi, Gainor, Justin F., Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
MET amplification (amp) as a resistance mechanism to osimertinib
Piotrowska, Zofia, Thress, Kenneth Stephen, Mooradian, Meghan, Heist, Rebecca Suk, Azzoli, Christopher G., Temel, Jennifer S., Rizzo, Coleen, Nagy, Rebecca J, Lanman, Richard B., Gettinger, Scott N., Evans, Tracey L., Hata, Aaron N., Shaw, Alice Tsang, Sequist, Lecia V.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Alectinib versus crizotinib in treatment-naive advanced ALK -positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
Shaw, Alice Tsang, Peters, Solange, Mok, Tony, Gadgeel, Shirish M., Ahn, Jin Seok, Ou, Sai-Hong Ignatius, Perol, Maurice, Dziadziuszko, Rafal, Kim, Dong-Wan, Rosell, Rafael, Zeaiter, Ali Hassan, Liu, Ting, Golding, Sophie, Balas, Bogdana, Noé, Johannes, Morcos, Peter N., Camidge, D. Ross
Published in Journal of clinical oncology (20.06.2017)
Published in Journal of clinical oncology (20.06.2017)
Get full text
Journal Article
Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC)
Puig, Oscar, Yang, James Chih-Hsin, Ou, Sai-Hong Ignatius, Chiappori, Alberto, Chao, Bo H, Belani, Chandra Prakash, Spira, Alexander I., Bearz, Alessandra, Duruisseaux, Michael, Allard, John, Birzele, Fabian, Boisserie, Frederic, Lonngren, Ulrika, Bordogna, Walter, Klass, Daniel M., Newman, Aaron M., Zeaiter, Ali Hassan, Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC)
Camidge, D. Ross, Bazhenova, Lyudmila, Salgia, Ravi, Langer, Corey J., Gold, Kathryn A., Rosell, Rafael, Shaw, Alice Tsang, Weiss, Glen J., Narasimhan, Narayana I., Dorer, David J., Rivera, Victor M., Clackson, Timothy Piers, Conlan, Maureen G, Kerstein, David, Haluska, Frank G., Gettinger, Scott N.
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article
Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC)
Janne, Pasi A., Shaw, Alice Tsang, Pereira, Jose Rodrigues, Jeannin, Gaelle, Vansteenkiste, Johan, Barrios, Carlos H., Franke, Fabio A., Grinsted, Lynda, Smith, Paul D., Zazulina, Victoria, Smith, Ian C., Crino, Lucio
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement
Shaw, Alice Tsang, Camidge, D Ross, Engelman, Jeffrey A., Solomon, Benjamin J., Kwak, Eunice Lee, Clark, Jeffrey W., Salgia, Ravi, Shapiro, Geoffrey, Bang, Yung-Jue, Tan, Weiwei, Tye, Lesley, Wilner, Keith D., Stephenson, Patricia, Varella-Garcia, Marileila, Bergethon, Kristin, Iafrate, A. John, Ou, Sai-Hong Ignatius
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Felip, Enriqueta, de Braud, Filippo G., Maur, Michela, Loong, Herbert H., Shaw, Alice Tsang, Vansteenkiste, Johan F., John, Thomas, Liu, Geoffrey, Lolkema, Martijn P., Selvaggi, Giovanni, Giannone, Vanessa, Cazorla, Pilar, Baum, Jason, Balbin, O. Alejandro, Wang, Luojun (Victor), Lau, Yvonne Y., Scott, Jeffrey W., Tan, Daniel Shao-Weng
Published in Journal of thoracic oncology (01.03.2020)
Published in Journal of thoracic oncology (01.03.2020)
Get full text
Journal Article
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK -positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses
Bearz, Alessandra, Martini, Jean-Francois, Jassem, Jacek, Kim, Sang-We, Chang, Gee-Chen, Shaw, Alice Tsang, Shepard, Deborah, Dall’O, Elisa, Polli, Anna, Thurm, Holger C., Zalcman, Gerard, Campelo, Rosario Garcia, Penkov, Konstantin, Hayashi, Hidetoshi, Solomon, Benjamin J.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Circulating free DNA as a prognostic biomarker in patients with advanced ALK + NSCLC treated with alectinib from the global phase III ALEX trial
Dziadziuszko, Rafal, Peters, Solange, Mok, Tony S. K., Camidge, D. Ross, Noé, Johannes, Nowicka, Malgorzata, Bordogna, Walter, Morcos, Peter N., Smoljanovic, Vlatka, Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors
Dagogo-Jack, Ibiayi, Rooney, Marguerite, Nagy, Rebecca, Digumarthy, Subba, Chin, Emily, Ackil, Jennifer, Gainor, Justin F., Lin, Jessica Jiyeong, Lanman, Richard B., Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
An artificial intelligence approach to variant calling of ALK resistance mutations
Lennerz, Jochen K, Chin, Emily, Rooney, Marguerite, Zomnir, Michael, Dominguez Meneses, Enrique, Lipkin, Lev, Iafrate, A. John, Le, Long P., Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies
Smart, Kevin, Hsu, Joy C, Jaminion, Felix, Guerini, Elena, Shaw, Alice Tsang, Zhou, Caicun, Mok, Tony S. K., Bordogna, Walter, Frey, Nicolas, Morcos, Peter N.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB–IIIA anaplastic lymphoma kinase-positive ( ALK +) non-small cell lung cancer (NSCLC)
Solomon, Benjamin J., Ahn, Jin Seok, Barlesi, Fabrice, Dziadziuszko, Rafal, Nishio, Makoto, Shaw, Alice Tsang, Bordogna, Walter, Meyenberg, Christoph, Wu, Yi-Long
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK + NSCLC
Peters, Solange, Mok, Tony S. K., Gadgeel, Shirish M., Rosell, Rafael, Dziadziuszko, Rafal, Kim, Dong-Wan, Perol, Maurice, Ou, Sai-Hong Ignatius, Shaw, Alice Tsang, Bordogna, Walter, Smoljanovic, Vlatka, Hilton, Magalie, Ruf, Thorsten, Archer, Venice Rosale, Camidge, D. Ross
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression
Dagogo-Jack, Ibiayi, Oxnard, Geoffrey R., Fink, Jessica, Diubaldi, Gianluca, Helms, Caitlyn, Gainor, Justin F., Rabin, Michael S., Heist, Rebecca Suk, Lin, Jessica Jiyeong, Ackil, Jennifer, Muzikansky, Alona, Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK + NSCLC
Lin, Jessica Jiyeong, Yeap, Beow Y., Ferris, Lorin A, Yoda, Satoshi, Dagogo-Jack, Ibiayi, Lennerz, Jochen K, Gainor, Justin F., Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC)
Dagogo-Jack, Ibiayi, Schrock, Alexa Betzig, Kem, Marina, Jessop, Nicholas, Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj Mahamed, Shaw, Alice Tsang, Mino-Kenudson, Mari
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI)
Piotrowska, Zofia, Cobb, Rosemary G., Banwait, Mandeep, Marcoux, Nicolas, Mooradian, Meghan, Dagogo-Jack, Ibiayi, Lin, Jessica Jiyeong, Heist, Rebecca Suk, Shaw, Alice Tsang, Gainor, Justin F., Sequist, Lecia V.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Efficacy of platinum-pemetrexed combination chemotherapy in ALK + non-small cell lung cancer refractory to second-generation ALK TKIs
Lin, Jessica Jiyeong, Schoenfeld, Adam Jacob, Zhu, Viola Weijia, Yeap, Beow Y., Chin, Emily, Rooney, Marguerite, Plodkowski, Andrew J., Digumarthy, Subba, Dagogo-Jack, Ibiayi, Gainor, Justin F., Ou, Sai-Hong Ignatius, Riely, Gregory J., Shaw, Alice Tsang
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article